John Tsai
Director/Board Member at BLUEPRINT MEDICINES CORPORATION
Net worth: 2 M $ as of 2024-03-30
Profile
Presently, John Tsai is Chief Medical Officer at Novartis AG. In his past career Dr. Tsai was Chief Medical Officer & SVP-Global Medical at Amgen, Inc. and Head-Clinical Development at Bristol Myers Squibb Co. He received a doctorate from the University of Louisville School of Medicine and an undergraduate degree from Washington University in St. Louis.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
NOVARTIS AG
0.00% | 2022-12-30 | 13,550 ( 0.00% ) | 1 M $ | 2024-03-30 |
| 2023-06-20 | 6,500 ( 0.01% ) | 616 590 $ | 2024-03-30 |
John Tsai active positions
| Companies | Position | Start |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Director/Board Member | 2023-01-05 |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Private Equity Investor | - |
| Forcefield Therapeutics Ltd. | Chief Executive Officer | 2023-09-26 |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Chairman | 2023-10-15 |
Former positions of John Tsai
| Companies | Position | End |
|---|---|---|
| NOVARTIS AG | Chief Tech/Sci/R&D Officer | 2022-05-14 |
| AMGEN INC. | Chief Tech/Sci/R&D Officer | 2017-12-31 |
| BRISTOL-MYERS SQUIBB COMPANY | Private Equity Investor | 2011-12-31 |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Director/Board Member | - |
Training of John Tsai
| Washington University in St. Louis | Undergraduate Degree |
| University of Louisville School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| NOVARTIS AG | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| Private companies | 4 |
|---|---|
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Health Technology |
| Forcefield Therapeutics Ltd. |
- Stock Market
- Insiders
- John Tsai
